Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: A double-blind, randomized, crossover study

Diabetes, Obesity and Metabolism

Volumn 11, Issue 1, 2009, Pages 69-71

  King, Allen B ^a  

^a Diabetes Care Center   (United States)

Author keywords

Basal insulin; Continuous glucose monitoring; Insulin detemir; Insulin glargine

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; GLUCOSE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; SITAGLIPTIN; SULFONYLUREA;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL;

EID: 58149199751     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.01014.x     Document Type: Article

References (5)

1. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins: An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007; 9: 648-659.
2. Porcellati F, Rossetti P, Busciantella NR et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: A double-blind, randomized, crossover study. Diabetes Care 2007; 30: 2447-2452.
3. King A, Merilinen M, Luddeke H. Insulin detemir in combination with OADs improves glycaemic control and reduces hypoglycaemia, without weight gain, in type 2 patients previously treated with OADs plus bedtime NPH or insulin glargine: Results from the PREDICTIVE™ study (P921). Diabet Med 2006; 23 (Suppl. 4): 333.
4. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomized, 52 week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetologia 2008; 51: 408-416.
5. Raskin P, Chaykin L, Mak C, Koenen C. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a treat-to-target study in people with type 2 diabetes. Diabet Med 2006; 23 (Suppl. 4): 341-342.